BACKGROUND This study was designed to explore the therapeutic potential of suppressing MAP kinase and PI3K/Akt pathways and histone deacetylase (HDAC) to induce the expression of sodium/iodide symporter (NIS) and radioiodine uptake in non-thyroid cancer cells. METHODS We tested the effects of the MEK inhibitor RDEA119, the Akt inhibitor perifosine, and the HDAC inhibitor SAHA on NIS expressio...

UNLABELLED Salivary gland dysfunction is one of the common side effects of high-dose radioiodine therapy for thyroid cancer. The purpose of this study was to determine whether an early start of sucking lemon candy decreases salivary gland injury after radioiodine therapy. METHODS The incidence of the side effects of radioiodine therapy on the salivary glands was prospectively and longitudinal...

BACKGROUND RADIOIODINE IS ROUTINELY USED OR PROPOSED FOR DIAGNOSTIC AND THERAPEUTIC PURPOSES: (123)I, (125)I and (131)I for diagnostics and (125)I and (131)I for therapy. When radioiodine-labelled pharmaceuticals are administered to the body, radioiodide might be released into the circulation and taken up by the thyroid gland, which may then be an organ at risk. The aim of this study was to com...

BACKGROUND Selectively increased radioiodine accumulation in thyroid cells by thyrotropin (TSH) allows targeted treatment of thyroid cancer. However, the extent of TSH-stimulated radioiodine accumulation in some thyroid tumors is not sufficient to confer therapeutic efficacy. Hence, it is of clinical importance to identify novel strategies to selectively further enhance TSH-stimulated thyroidal...

(131)I is an integral component in postsurgical management of well-differentiated thyroid cancer (WDTC), which includes papillary and follicular types. (131)I is used postsurgically to either destroy remaining thyroid tissue (thyroid ablation) or to treat recurrence and metastases (radioiodine therapy). (131)I is no longer a routine diagnostic modality, but it is widely used for remnant ablatio...

Recombinant human thyroid-stimulating hormone (rhTSH) was approved for diagnostic testing by the U.S. Food and Drug Administration in November 1998. It has subsequently been approved in Europe and Australia and is available in many other countries on a restricted basis. Approval was based on its ability to stimulate the uptake of radioiodine into thyroid remnants and metastases of thyroid cance...

One of the earliest uses of radioiodine was as a tool for the study of thyroid physiology (1-7). Estimations of the relative quantities of isotope stored in the thyroid have been made by means of a Geiger-Muller tube held over the gland and by determining the amount present in the urine and blood. The rate with which the level of radioiodine changes in these compartments has also been studied (...

In this issue of the Journal, Schlumberger et al.1 and Mallick et al.2 describe the administration of radioiodine (iodine-131) after total thyroidectomy in patients with low-risk thyroid cancer. Postsurgical treatment has long played an important role in the management of this increasingly common cancer.2 In the United States, the incidence nearly tripled (from 2.7 to 7.7 cases per 100,000) fro...

BACKGROUND Radioiodine treatment of hyperthyroidism in Graves' disease patients may cause or aggravate the course of ophthalmopathy (GO). We evaluated the activity and severity of ophthalmopathy in patients who acquired GO following radioiodine therapy. MATERIAL AND METHODS Between 2003 and 2005, 763 Graves' disease patients (50.9% of the total number of 1,500 patients referred to our Departm...

INTRODUCTION The treatment of amiodarone-induced thyrotoxicosis (AIT) still remains a clinical challenge, requiring the cooperation of both endocrinologists and cardiologists. Unfortunately, even today AIT is related to significantly increased mortality. OBJECTIVES The aim of this study was to compare the efficacy of radioidine therapy for type II AIT in 2 groups of patients: with high or nor...